Advertisement
 
News
Advertisement

DPX-Survivac Produces Immune Responses in Cancer Patients

Fri, 01/18/2013 - 11:34am

Immunovaccine Inc., a clinical stage vaccine company, reported positive results from a Phase 1 clinical study of the company’s cancer vaccine, DPX-Survivac, for the treatment of ovarian cancer.  The analysis, which now includes all patients enrolled in the study, confirmed previously reported results and uncovered new findings which are highlighted as follows:

• All patients receiving the DPX-Survivac combination therapy who were evaluable by tetramer staining (n=10) produced survivin-specific CD8 T cells following one or two vaccinations. Importantly the CD8 responses were maintained with booster vaccinations. The activation and maintenance of these specific immune cells is of particular interest in immunotherapy since CD8 T cells are implicated in identifying cancer cells, infiltrating tumors and killing cancer targets.
• All patients receiving the DPX-Survivac combination therapy (n=12) demonstrated antigen specific immune responses as measured by at least one of the study’s three immune monitoring assays (ELISpot, tetramer analysis and multiparametric intracellular cell staining). In 11 of 12 patients, the immune responses were confirmed by two assays (five patients) or three assays (six patients) performed. These immune responses were established with one or two vaccinations and further increased or maintained with follow-up booster vaccinations. 
• Analysis of immune responses by ELISpot showed that a cohort of patients receiving the higher dose of the vaccine therapy produced an average stimulation factor of greater than 600 times (600x) over baseline following their third vaccination.   For one of these patients, the stimulation factor reached greater than 1,200 times (1,200x) over baseline.

These immune responses are in agreement with the previously reported average increase of 350 times (350x) over baseline for these same patients following their second vaccination.

• DPX-Survivac was deemed well tolerated with no significant systemic adverse events reported in any patients recruited in this study. Reported adverse events were restricted to injection site reactions, which were experienced by the majority of patients after repeated vaccinations.  Those patients presenting the strongest immune responses were more likely to exhibit more pronounced injection site reactions.  There were no dose limiting toxicities experienced during the trial and no patient withdrew consent due to adverse events.

“Our clinical trial data has identified a treatment cohort that consistently produces strong CD8 T cell responses that are clearly detected in the circulation of vaccinated patients,” said Marc Mansour, chief science officer of Immunovaccine. “The fact that DPX-Survivac is able to generate and maintain the desired tumor killing T cells provides strong fundamentals for advancing the clinical development of this novel vaccine.”

The Phase 1 DPX-Survivac trial was a multi-center, open-label, dose-ranging study in previously diagnosed ovarian cancer patients who had been treated by surgery and chemotherapy.   Under the study protocol, these patients each received a total of three DPX-Survivac vaccinations three weeks apart with a total of 18 ovarian cancer patients completing all three vaccinations. A lead-in cohort of three patients received DPX-Survivac alone to confirm the safety of the vaccine as a monotherapy. Two additional cohorts of six patients each received a low dose or a high dose of DPX-Survivac in combination with a low dose of cyclophosphamide. The trial’s primary objective was to evaluate the safety of the vaccine and in combination with cyclophosphamide.  A secondary endpoint was the evaluation of the immune response produced by the vaccine therapy. 

The Phase 1 study is part of a Phase 1/2 trial cleared by the U.S. FDA and Health Canada.  The Phase 2 portion of the trial will be a randomized, double-blinded, placebo-controlled study with a vaccine dose selected based on the Phase 1 results.  The Phase 2 trial will assess the clinical benefit of DPX-Survivac in patients with advanced ovarian cancer.

The positive results in the company's cancer vaccine program follow immediately on the heels of the Company’s announcement of similarly strong results from its infectious disease program.  Last week, Immunovaccine announced that data from an immunogenicity study of anthrax vaccines formulated in the Company’s DepoVax adjuvanting platform showed DepoVax-based vaccines provided a more rapid and long lasting immune response as compared to the licensed anthrax vaccine BioThrax.  The two studies both leveraged the same DepoVax platform to enhance immune response sharply in different vaccines targeting different indications. 

"We're encouraged that the data continues to accumulate showing IMV's technology can speed up immune responses and make them stronger and longer lasting, for a wide range of vaccines," said John Trizzino, chief executive officer of Immunovaccine. "Whether in cancer immunotherapy or in protection against infectious disease, the results are very positive."

Date: January 7, 2013
Source: Immunovaccine Inc.

Topics

Advertisement

Share This Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading